Home Alzheimer’s Disease Psychological Responses to Genetic Counseling, Multigene Panel Testing Reveals Low Patients Distress,...

Psychological Responses to Genetic Counseling, Multigene Panel Testing Reveals Low Patients Distress, Uncertainty

Among an ethnically and socioeconomically diverse population of individuals undergoing genetic counseling and multigene panel testing for hereditary cancer risk, investigators found that psychological response corresponded to test results and demonstrated low distress and uncertainty.

This study, published in Cancer, is one of the first to demonstrate that moderate-risk pathogenic variant (PV) carriers experience outcomes similar to that of high-risk PVs without higher levels of uncertainty. These results may help to identify the various concerns of individuals undergoing panel testing and ways to support their needs.

“The overall reaction to panel testing corresponded to test results and did not show concerning levels of uncertainty or distress,” wrote the study authors, who were led by Julie O. Culver, MS. “Although PV carriers did experience more psychological distress than…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments